Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

BACKGROUND: RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This final overall survival (OS) analysis evaluate...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Oncol
Autors principals: Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T., Srimuninnimit, V., Pittman, K., Sabbatini, R., Rha, S. Y., Flaig, T. W., Page, R. D., Beck, J. T., Cheung, F., Yadav, S., Patel, P., Geoffrois, L., Niolat, J., Berkowitz, N., Marker, M., Chen, D., Motzer, R. J.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5452072/
https://ncbi.nlm.nih.gov/pubmed/28327953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx075
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars